• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[白血病与营养不良。II. 维持化疗强度作为标准风险急性淋巴细胞白血病患者生存预后因素的研究]

[Leukemia and malnutrition. II. The magnitude of maintenance chemotherapy as a prognostic factor in the survival of patients with standard-risk acute lymphoblastic leukemia].

作者信息

Lobato-Mendizábal E, Ruiz-Argüelles G J

机构信息

Hospital Universitario de Puebla, México.

出版信息

Rev Invest Clin. 1990 Apr-Jun;42(2):81-7.

PMID:2267453
Abstract

In previous papers we have shown that malnutrition is an adverse prognostic factor in the outcome of treatment in patients with standard-risk acute lymphoblastic leukemia. The reason why undernourished children do poorly as compared with well nourished children is that malnourishment leads to a diminished bone marrow reserve thus making necessary to delivery of suboptimal doses of maintenance chemotherapy (less than that calculated according to body surface). Undernourished children receive less 6-MP and MTX and relapse more frequently in the bone marrow, finally reflecting a 5 yr disease-free survival of 26% as compared with 83% in well-nourished children (p less than 0.001). In this paper we have analyzed the impact of the variable delivery of sub-optimal doses of maintenance chemotherapy in a group of 43 pediatric patient with standard-risk acute lymphoblastic leukemia. The 5 year disease free survival of children receiving suboptimal maintenance chemotherapy was 7% as compared with 65% for those receiving full doses of both 6-MP and MTX (p less than 0.001), and more frequent relapse involving the bone marrow in children receiving low doses (71% versus 3%, p = 0.000005). The impact of the variable suboptimal doses of chemotherapy was present in children with both normal and deficient nourishment status. It is concluded that the delivery of suboptimal doses of maintenance chemotherapy, due to bone marrow toxicity related to an abnormal myelopoietic reserve, is an adverse prognostic factor in the outcome to treatment of patients with lymphoblastic leukemia.

摘要

在之前的论文中,我们已经表明,营养不良是标准风险急性淋巴细胞白血病患者治疗结果中的一个不良预后因素。与营养良好的儿童相比,营养不良的儿童预后较差的原因在于,营养不良会导致骨髓储备减少,从而使得维持化疗只能给予次优剂量(低于根据体表面积计算的剂量)成为必要。营养不良的儿童接受的6-巯基嘌呤(6-MP)和甲氨蝶呤(MTX)较少,骨髓复发更为频繁,最终导致5年无病生存率为26%,而营养良好的儿童为83%(p<0.001)。在本文中,我们分析了次优剂量维持化疗的不同给药方式对一组43例标准风险急性淋巴细胞白血病儿科患者的影响。接受次优维持化疗的儿童5年无病生存率为7%,而接受全剂量6-MP和MTX的儿童为65%(p<0.001),并且接受低剂量化疗的儿童骨髓复发更为频繁(71%对3%,p=0.000005)。化疗剂量次优变化的影响在营养状况正常和营养不足的儿童中均存在。结论是,由于与异常骨髓造血储备相关的骨髓毒性,给予次优剂量的维持化疗是淋巴细胞白血病患者治疗结果的一个不良预后因素。

相似文献

1
[Leukemia and malnutrition. II. The magnitude of maintenance chemotherapy as a prognostic factor in the survival of patients with standard-risk acute lymphoblastic leukemia].[白血病与营养不良。II. 维持化疗强度作为标准风险急性淋巴细胞白血病患者生存预后因素的研究]
Rev Invest Clin. 1990 Apr-Jun;42(2):81-7.
2
[Leukemia and malnutrition. III. Effect of chemotherapeutic treatment on the nutritional state and its repercussion on the therapeutic response of patients with acute lymphoblastic leukemia with standard risk].
Sangre (Barc). 1990 Jun;35(3):189-95.
3
Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia: a report of the CCG-161 study by the Childrens Cancer Study Group.长春新碱和泼尼松的每月脉冲式给药可预防低危儿童急性淋巴细胞白血病的骨髓和睾丸复发:儿童癌症研究组CCG - 161研究报告
J Clin Oncol. 1991 Jun;9(6):1012-21. doi: 10.1200/JCO.1991.9.6.1012.
4
[Malnutrition is an adverse prognostic factor in the response to treatment and survival of patients with acute lymphoblastic leukemia at the usual risk].营养不良是普通风险急性淋巴细胞白血病患者治疗反应及生存的不良预后因素。
Gac Med Mex. 1991 Mar-Apr;127(2):125-31; discussion 131-2.
5
Leukaemia and nutrition. I: Malnutrition is an adverse prognostic factor in the outcome of treatment of patients with standard-risk acute lymphoblastic leukaemia.
Leuk Res. 1989;13(10):899-906. doi: 10.1016/0145-2126(89)90043-x.
6
Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.鞘内注射甲氨蝶呤可替代颅脑照射,用于预防接受基于柏林-法兰克福-明斯特方案的强化化疗的中危急性淋巴细胞白血病患儿的中枢神经系统复发。意大利儿科血液学和肿瘤学协会。
J Clin Oncol. 1995 Oct;13(10):2497-502. doi: 10.1200/JCO.1995.13.10.2497.
7
Randomized trial to compare LSA2L2-type maintenance therapy to daily 6-mercaptopurine and weekly methotrexate with vincristine and dexamethasone pulse for children with acute lymphoblastic leukemia.比较 LSA2L2 型维持治疗与每日 6-巯基嘌呤和每周甲氨蝶呤联合长春新碱和地塞米松脉冲治疗儿童急性淋巴细胞白血病的随机试验。
Pediatr Blood Cancer. 2010 Aug;55(2):239-47. doi: 10.1002/pbc.22528.
8
Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children.巯嘌呤的全身暴露作为儿童急性淋巴细胞白血病的一个预后因素。
N Engl J Med. 1990 Jul 5;323(1):17-21. doi: 10.1056/NEJM199007053230104.
9
Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study.中剂量静脉注射甲氨蝶呤和巯嘌呤治疗儿童非T、非B急性淋巴细胞白血病:一项儿科肿瘤学组的研究
J Clin Oncol. 1989 Oct;7(10):1539-44. doi: 10.1200/JCO.1989.7.10.1539.
10
Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study.大剂量静脉注射甲氨蝶呤和巯嘌呤治疗高危非T、非B急性淋巴细胞白血病:一项儿科肿瘤学组研究。
J Clin Oncol. 1994 Jul;12(7):1383-9. doi: 10.1200/JCO.1994.12.7.1383.

引用本文的文献

1
Recent nanotechnology advancements to treat multidrug-resistance pancreatic cancer: Pre-clinical and clinical overview.治疗多药耐药性胰腺癌的纳米技术最新进展:临床前和临床概述。
Front Pharmacol. 2022 Aug 24;13:933457. doi: 10.3389/fphar.2022.933457. eCollection 2022.